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Objectives/background: Myelodysplastic syndromes (MDSs) are a heterogeneous disease in
terms of clinical course and response to therapy. Epigenetic changes are the primary mecha-
nism of MDS pathogenesis. FOXO3 and CHEK2 genes play significant roles in normal cellular
mechanisms and are also known as tumor suppressor genes. We aimed to clarify the correlation
of epigenetic changes in these genes with clinicopathologic findings in MDS.
Methods: A total of 54 newly diagnosed MDS patients referred to Shariati and Firouzgar Hospi-
tals (Tehran, Iran) were included in the study from 2013 to 2015, comprising the following
cases: 26 with refractory cytopenia with unilineage dysplasia, 10 with refractory cytopenia with
multilineage dysplasia, four refractory anemia with excess blasts-1 (RAEB-1), 11 refractory ane-
mia with excess blasts-2 (RAEB-2), and three MDS associated with isolated deletion (5q-). Risk
Epigenetic changes in FOXO3 and CHEK2 genes 215groups were determined according to the Revised International Prognostic Scoring System
(IPSS-R). The methylation status of CHEK2 and FOXO3 promoters were determined by
methylation-sensitive high-resolution melting analysis of sodium bisulfite-converted DNA.
Expressions of CHEK2, FOXO3, and GAPDH were measured by quantitative real-time polymerase
chain reaction and fold changes were calculated using the DDCT method.
Results: Statistical analysis revealed no promoter methylation of CHEK2 and FOXO3 in healthy
control specimens. FOXO3 promoter methylation was associated with high-risk World Health
Organization subgroups (p = .017), high-risk IPSS-R (p = .007), high-risk cytogenetics
(p = .045), and more than 5% blasts in bone marrow (p = .001). CHEK2 promoter methylation
was correlated with more than 5% blasts in bone marrow (p = .009).
Conclusions: Promoter methylation of CHEK2 and especially FOXO3 is associated with adverse
clinicopathological findings and disease progression in MDS.
 2020 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Myelodysplastic syndromes (MDSs; OMIM 614286) represent
a heterogeneous group of myeloid neoplasms defined by
peripheral cytopenia, ineffective hematopoiesis, morpho-
logic dysplasia in hematopoietic lineages, and genetic insta-
bility with a potential transformation to secondary acute
myeloid leukemia (AML; OMIM 601626) [1]. The pathogene-
sis of MDS and its transformation to AML is not well deter-
mined yet. Epigenetic changes play the central role in MDS
pathogenesis, such as in self-renewal of MDS-initiating cells,
impaired differentiation of MDS cells, progression to AML,
and apoptotic defects in MDS cells. The epigenetic changes,
mostly promoter hypermethylation of tumor suppressor
genes, are well known as a mechanism that contributes to
the malignant phenotype of neoplasms. Recently, most
studies have focused on epigenetic impairments of tumor
suppressor genes in MDS [2,3]. Cell cycle checkpoint kinase
2 (CHK2, also known as ‘‘CHEK2”) is a tumor suppressor pro-
tein encoded by the CHEK2 gene (OMIM 604373), located on
the long arm of chromosome 22 (locus 22q12.1). CHEK2 is a
multifunctional kinase that is responsible for monitoring cell
cycle checkpoint control and DNA damage response [4]. The
activated checkpoints delay cell cycle progression to facili-
tate DNA repair or induce cell death, and thereby impede
the development of cancers [5]. Somatic mutations of the
CHEK2 gene have been found in subsets of diverse types of
human cancers including breast, lung, vulva, colon, ovary,
osteosarcoma, MDS, and lymphomas [4,5].
Forkhead box O3, also known as FOXO3 or FOXO3a, is a
human protein encoded by the FOXO3 gene (OMIM 602681)
on chromosome 6 (6q21) and belongs to the O subclass of
the Forkhead family of transcription factors. The FOXO fam-
ily is a direct downstream target of AKT (Protein kinase B
(PKB)) that has an essential regulatory role in diverse biolog-
ical processes [6]. In the absence of active AKT, FOXOs
localize to the nucleus where they regulate the transcrip-
tion of genes involved in cell cycle arrest, apoptosis, and
tumor suppression [7]. Many studies have revealed that
post-translational modifications including phosphorylation,
acetylation, ubiquitination, and arginine methylation have
essential roles in the regulation of FOXO’s activity [8–10].Hypermethylation has been implicated as an essential
and causal factor in the pathophysiology of several cancers.
Despite this, the role of promoter hypermethylation of
FOXO3 has been studied rarely in hematologic neoplasms.
This study focused on whether the methylation of FOXO3
and CHEK2 changes their expression in patients with MDS.
Correlations with clinicopathological findings, MDS sub-
groups, and risk stratification system (Revised International
Prognostic Scoring System-[IPSS-R]) were also evaluated.
We applied high-resolution melting (HRM) analysis and
real-time polymerase chain reaction (RT-PCR) to assess




A total of 54 patients with MDS referred to Shariati and
Firouzgar Hospitals (Tehran, Iran) were included in the
study after obtaining informed consent (from 2013 to
2015). The diagnosis of MDS was made by peripheral blood
and bone marrow findings, according to the World Health
Organization (WHO) classification, as well as by conven-
tional cytogenetic analysis. Clinical features of the patients
are listed in Table 1. The study population included 54 pri-
mary MDS cases comprising 26 cases of refractory cytopenia
with unilineage dysplasia, 10 cases of refractory cytopenia
with multilineage dysplasia (RCMD), four cases of refractory
anemia with excess blasts-1 (RAEB-1), 11 cases of refractory
anemia with excess blasts-2 (RAEB-2), and three cases of
MDS associated with isolated deletion (5q-).
Risk groups were determined according to the IPSS-R for
all 54 cases (Table 1).
Conventional cytogenetic analysis
Conventional cytogenetic investigation was carried out for
54 patients. Chromosomes were prepared by a culture of
bone marrow cells. Karyotypes were investigated on banded
metaphases according to what has been previously
described. Chromosome abnormalities were reported
Table 1 Patient demographics (n = 54).
Characteristics Median (interquartile range) n




Absolute neutrophil count (109/L) 2.33 (2.2)
Hemoglobulin (g/dL) 9.45 (1.9)
Platelets (109/L) 105 (115)






















5q- = MDS associated with isolated deletion; IPSS-R = Revised International Prognostic Scoring System; RAEB-1 = refractory anemia with
excess blasts-1; RAEB-2 = refractory anemia with excess blasts-2; RCMD = refractory cytopenia with multilineage dysplasia; RCUD = re-
fractory cytopenia with unilineage dysplasia.
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netic Nomenclature [11].
Genomic DNA isolation
Genomic DNA was isolated from all samples using the
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany)
according to manufacturer’s recommendations.
Bisulfite conversion and analysis of promoter
methylation by methylation-sensitive HRM
To convert DNA, EpiTect Bisulfite Kit (Qiagen) was used fol-
lowing the manufacturer’s specifications; 1 lg of DNA from
each sample was used for conversion.
The methylation status of CHEK2 and FOXO3 promoters
was determined by methylation-sensitive HRM (MS-HRM) of
sodium bisulfite–converted DNA. The obtained modified
DNA was analyzed by MS-HRM using two sets of primers for
CHEK2 and FOXO3. The MS-HRM was carried out as previ-
ously described [11].
We included in each assay 20 normal blood samples and
EpiTect PCR Control DNA (Qiagen) as control.RNA extraction and quantitative RT-PCR
RNA from mononuclear cells of all samples was extracted
and converted to complementary DNA. The CHEK2, FOXO3,
and GAPDH expressions were measured by quantitative RT-
PCR (qRT-PCR) in triplicate on Rotor-Gene 6000 (Corbett
Research, Mortlake, Australia). The fold changes were cal-
culated using the DDCT method.
Statistical analysis
Statistical analysis was performed using SPSS version 17
(IBM, New York, NY, USA). Normality of variables was
evaluated by the Kolmogorov–Smirnov test. The associa-
tions of methylation/unmethylation status with WHO sub-
groups, IPSS-R risk stratification, and cytogenetic risk
subgroups were examined by the chi-square test. Associ-
ations of bone marrow blast percentage with methylation
frequency and gene expression with promotor methyla-
tion/unmethylation were analyzed by the Mann–Whitney
U test. For all analyses, the p values were two tailed,
and all p values 0.05 were considered statistically
significant.
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Demographics of patients
A total of 54 patients with a median age of 61.56 were
included in this study. Demographic and hematologic find-
ings are presented in Table 1.Methylation analysis
Promoter methylation of FOXO3 and CHEK2 genes
The methylation profile of FOXO3 and CHEK2 genes in
patients with MDS and controls was studied by MS-HRM on
bisulfite-treated DNA. All melting curves were compared
individually with methylated/unmethylated commercial
controls (EpiTect; Qiagen).
The number of methylated cases in the MDS group was 30
(55.6%) and eight (14.8%) for CHEK2 and FOXO3, respec-
tively. Both genes were determined to be unmethylated in
all normal samples.
In our patients, all the subtypes included in this study
showed the CHEK2 methylation pattern (p = .368), whereas
only RCMD, RAEB-1, and RAEB-2 subgroups showed the
FOXO3 methylation pattern (p = .017). However, a higher
frequency of the two-gene hypermethylation was encoun-
tered in patients with RAEB-1 and RAEB-2 subtypes as com-
pared with other subtypes (Table 2; chi-square analysis).
CHEK2 methylation was studied in different IPSS-R sub-
types (chi-square analysis). Aberrant methylation of CHEK2
in different subtypes showed a higher incidence of methy-
lated CHEK2 in the IPSS-R high-risk subgroup and a lower
incidence of methylated CHEK2 in the IPSS-R very low and
low subgroups, but these results were not statistically sig-
nificant (p = .45). This analysis showed a significant associ-
ation between FOXO3 promoter methylation and IPSS-R
high-risk subgroups (p = .007; Table 3). Data also illustrated
a significant association between cytogenetic and FOXO3
methylation (p =.045) and bone marrow blast percentage
and FOXO3 methylation (p = 0.001) (Table 4 and Fig. 1).
Statistical analysis comparing CHEK2 and FOXO3 methy-
lation with clinical factors revealed a significant association
between methylation and bone marrow blast percentage of
more than 5% (p = .009 and 0.001, respectively; Fig. 1).Table 2 CHEK2 and FOXO3 methylation/unmethylation status in
Gene WHO subtypes (n)
RCUD (26) RCMD (10) RAEB-1 (4)
FOXO3
Met (%) 0 20 25
Unmet (%) 100 80 75
CHEK2
Met (%) 42.3 70 75
Unmet (%) 57.7 30 25
5q- = MDS associated with isolated deletion; RAEB-1 = refractory anem
blasts-2; RCMD = refractory cytopenia with multilineage dysplasia; RCU
Health Organization.Messenger RNA expression by RT-PCR
To investigate the association between DNA methylation
and messenger RNA (mRNA) expression, mRNA levels were
detected using qRT-PCR in the MDS and control samples
(Fig. 2).
Discussion
MDS is a highly heterogeneous disease in terms of pathogen-
esis and response to treatment. Epigenetic changes in tumor
suppressor genes is likely to play a role in the pathogenesis
and progression of MDS. The FOXO3A gene product is a tran-
scription factor which exhibits its effects by regulation of
expression of proapoptotic genes such as FasL and TRAIL
[12,13]. Our study revealed FOXO3 promoter methylation
in 14.8% of patients, which significantly differs among
WHO subgroups (p = .015). The more aggressive the sub-
groups, the more promoter methylation were detected.
Promoter methylation frequency decreased from RAEB-2 >
RAEB-1 > RCMD, respectively. Other subgroups showed no
evidence of FOXO3 promoter methylation. Like the correla-
tion with WHO subgroups, there was also a significant statis-
tical association between FOXO3 promoter methylation
levels and IPSS-R stratification subgroups, especially in
patients with FOXO3 promoter methylation. High-risk IPSS-
R patients (poor and very poor) were associated with higher
promoter methylation (p = .022). Levels of promoter methy-
lation are well correlated with diminished gene expression
in patients who demonstrate FOXO3 promoter methylation
(p = .001). However, this result should be accepted with
caution because its effect size is minimal (–0.48) and 95%
confidence interval for effect size contained the 0 (statisti-
cal nonsignificance). Unexpectedly, 12 of 18 patients with
low levels of FOXO3 mRNA showed no evidence of promoter
methylation. This could be a result of genetic deletions
and/or effects of noncoding RNAs. There were no associa-
tions of FOXO3 mRNA levels with WHO subgroups, IPSS-R
stratification, and other clinicopathological findings in the
total cohort. To the best of our knowledge, this is the first
report of the association between FOXO3 promoter methy-
lation and high-risk MDS. In line with our findings, other
tumors such as hepatocellular and ovarian carcinomas with
low expression of FOXO3 were associated with poor progno-
sis and high-risk disease [14,15]. However, Santamaria andWHO subgroups.
Chi square/p value







ia with excess blasts-1; RAEB-2 = refractory anemia with excess
D = refractory cytopenia with unilineage dysplasia; WHO = World
Fig. 2 CHEK2 expression is reduced in patients with promotor
methylation (p < .001). Met; methylation. Unmet;
unmethylation.
Table 3 CHEK2 and FOXO3 methylation/unmethylation status in the IPSS-R prognostic category.
Gene IPSS-R prognostic category (n) Chi square/p value
Very low (20) Low (13) Intermediate (8) High (4) Very high (9)
FOXO3 0.007
Met (%) 0 7.7 12.5 50 44.4
Unmet (%) 100 92.3 87.5 50 55.6
CHEK2 0.455
Met (%) 45 46.1 75 75 66.6
Unmet (%) 55 53.9 25 25 33.4
Note: IPSS-R = Revised International Prognostic Scoring System.
Table 4 CHEK2 and FOXO3 methylation/unmethylation status in cytogenetic risk subgroups.
Gene Cytogenetic risk subgroups (n) Chi square/p value
Very good (4) Good (36) Intermediate (8) Poor (3) Very poor (3)
FOXO3 0.045
Met (%) 0 8.3 25 66.6 33.3
Unmet (%) 100 91.7 75 33.4 66.7
CHEK2 0.731
Met (%) 50 50 50 66.6 66.6
Unmet (%) 50 50 50 33.4 33.4
Fig. 1 Association of methylation frequency of CHEK2 and
FOXO3 genes with bone marrow blast percentage.
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associated with adverse prognosis and increased relapse risk
in AML patients with normal cytogenetics [16]. Although
FOXO3 is a tumor suppressor, reasons for paradoxical
effects of FOXO3 overexpression and adverse prognosis in
AML are not well known, and further investigations are
needed. High expression of FOXO3 did not mean higher
activity of the FOXO3 protein. Some studies show that
FOXO3 hyperphosphorylation and subsequent abnormal
intracellular localization and functional disruption in AML
and MDS cell lines and patient-derived leukemic cells can
be corrected by treatment with low-dose hypomethylating
agents [8,9]. In the case of MDS, hypomethylating agents
also induced expression and promoter demethylation of
the FOXO3 gene [9]. Collectively, these data emphasize
the role of FOXO3 aberrations in the pathogenesis and pro-
gression of MDS.
CHEK2 belongs to the DNA damage response (DDR) sys-
tem (ATM/CHEK2-p53 pathway), which is activated by ATM
and results in cell cycle arrest or apoptosis due to DNA dam-
age [17,18]. CHEK2 showed tumor suppressor activities, and
some studies demonstrate epigenetic changes in the CHEK2
gene during MDS progression [19]. Our findings revealed pro-
moter methylation in 55.6% of MDS specimens. Hopfer and
colleagues also demonstrated CHEK2 promoter methylation
in 34+ progenitor cells of 13 patients with MDS [19]. How-
ever, analysis of non-Hodgkin lymphoma patients by Tort
et al. revealed no evidence of CHEK2 promoter methylation
[20]. Some studies demonstrated the role of CHEK2 pro-
moter methylation in tumor progression [21,22]. A recent
study by Popp and colleagues revealed abnormal DNA dam-
age response and distorted and diminished expression of
CHEK2 protein in MDS and AML samples. They suggest the
main role for the Ataxia-telangiectasia-mutated (ATM) and
Epigenetic changes in FOXO3 and CHEK2 genes 219ataxia telangiectasia and Rad3-related (ATR) pathway and
its downstream proteins in the progression of MDS [23]. In
our study, the bone marrow blast infiltration (>5%) was asso-
ciated with CHEK2 promoter methylation (p = .009). There
was also a considerable association between CHEK2 pro-
moter methylation and reduced gene expression
(p < .001). Other clinicopathological findings showed no
associations with CHEK2 promoter methylation and
expression.
In conclusion, our results provide evidence for epigenetic
silencing of FOXO3 and CHEK2 genes in MDS samples when
compared with healthy specimens. These alterations in
FOXO3 are associated with MDS progression and risk sub-
groups, whereas CHEK2 promoter methylation is associated
with blast percentage in the bone marrow. Further evalua-
tions are needed to elucidate the exact role of epigenetic
changes in FOXO3 and CHEK2 genes with respect to patho-
genesis and progression of MDS.Declaration of Competing Interest
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